Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State

Journal of Opioid Management

Volumn 5, Issue 5, 2009, Pages 257-286

  Aggarwal, Sunil K ^a   Carter, Gregory T ^b   Sullivan, Mark ^b   ZumBrunnen, Craig ^a   Morrill, Richard ^a   Mayer, Jonathan D ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabinoids; Cannabis; Chronic pain; Marijuana; Opiates; Opioids

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; AMITRIPTYLINE; BACLOFEN; CANNABIS; CARBAMAZEPINE; CELECOXIB; CITALOPRAM; CLONAZEPAM; CODEINE; DIHYDROERGOTAMINE MESILATE; ELETRIPTAN; ESCITALOPRAM; EXCEDRIN; GABAPENTIN; HYDROCODONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; LOPERAMIDE; METHADONE; MORPHINE; NAPROXEN; NARATRIPTAN; OPIATE; OXYCODONE; PARACETAMOL; PERCOCET; PETHIDINE; PREGABALIN; RIZATRIPTAN; ROFECOXIB; SUMATRIPTAN SUCCINATE; TEMAZEPAM; TRAMADOL; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTOREN;

ADULT; AGED; ALLERGY; ALLODYNIA; ANALGESIA; ARTHRALGIA; ARTICLE; BACKACHE; CANCER PAIN; CARPAL TUNNEL SYNDROME; CHRONIC PAIN; CONSTIPATION; DIABETIC NEUROPATHY; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERANCE; DRUG USE; FACE MUSCLE; FEMALE; FIBROMYALGIA; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; GENDER; GROUPS BY AGE; HEADACHE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HELP SEEKING BEHAVIOR; HIP PAIN; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERACTIVITY; HYPERALGESIA; INTESTINE OBSTRUCTION; INTRACTABLE PAIN; IRRITABILITY; ISCHIALGIA; KNEE PAIN; LEG PAIN; LEGAL ASPECT; LIMB PAIN; LOW BACK PAIN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MCGILL PAIN QUESTIONNAIRE; MEDICAL DOCUMENTATION; MEDICAL RECORD REVIEW; MIGRAINE; MYALGIA; NAUSEA; NECK PAIN; NERVE COMPRESSION; NERVOUSNESS; NEUROPATHIC PAIN; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PAIN CLINIC; PATIENT CARE; PERIPHERAL NEUROPATHY; PHANTOM PAIN; PHYSICIAN; RADICULAR PAIN; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SHOULDER PAIN; SIDE EFFECT; SOMNOLENCE; SPINAL CORD INJURY; TREATMENT DURATION; TREATMENT FAILURE; UNITED STATES; VISCERAL PAIN; VOMITING;

EID: 72449188656     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2009.0028     Document Type: Article

References (46)

1. "Workshop on the medical utility of marijuana," Report to the Director, National Institutes of Health, by the Ad Hoc Group of Experts, August 1997. Available at www.nih.gov/news/medmarijuana/MedicalMarijuana.htm. Accessed May 10, 2009.
2. American College of Physicians: "Supporting research into the therapeutic role of marijuana," A Position Paper, January 2008, with July 2008 Addendum. Available at www.acponline.org/advocacy/where-we-stand/other- issues/medmarijuana.pdf. Accessed May 10, 2009.
3. Joy JE, Watson SJ, Benson JA (eds.): Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press, 1999. Available at www.nap.edu/html/marimed. Accessed May 10, 2009.
4. Hanus LO: Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med Res Rev. 2009; 29: 213-271.
5. Pacher P, Batkai S, Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006; 58: 389-462. (Pubitemid 44394908)
6. Aggarwal SK, Carter GT, Sullivan M, et al.: Medicinal use of cannabis in the United States: Historical perspectives, current trends, future directions. J Opioid Manag. 2009; 5(3): 153-168.
7. Ellis RJ, Toperoff W, Vaida F, et al.: Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. Neuropsychopharmacology. 2009; 34(3): 672-680.
8. Wilsey B, Marcotte T, Tsodikov A, et al.: A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008; 9: 506-521.
9. Abrams DI, Jay CA, Shade SB, et al.: Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology. 2007; 68: 515-521.
10. Malfait AM, Gallily R, Sumariwalla PF, et al.: The nonpsychoactive cannabis constituent cannabidiol is an oral antiarthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA. 2000; 97: 9561-9566. (Pubitemid 30650815)
11. Rog DJ, Nurmiko T, Friede T, et al.: Randomized controlled trial of cannabis based medicine in central neuropathic pain due to multiple sclerosis. Neurology. 2005; 65: 812-819. (Pubitemid 41362120)
12. Abrams DI, Hilton JF, Leiser RJ, et al.: Short-term effects of cannabinoids in patients with HIV-1 infection. A randomized, placebo-controlled clinical trial. Ann Intern Med. 2003; 139: 258-266.
13. Lynch ME, Young J, Clark AJ: A case series of patients using medicinal marihuana for management of chronic pain under the Canadian Marihuana Medical Access Regulations. J Pain Symptom Manag. 2006; 32: 497-501. (Pubitemid 44755111)
14. Ko MC, Woods JH: Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: A peripheral cannabinoid action. Psychopharmacology. (Berl) 1999; 143: 322-326.
15. Berman JS, Symonds C, Birch R: Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomized controlled trial. Pain. 2004; 112: 299-306. (Pubitemid 39550730)
16. Agarwal N, Pacher P, Tegeder I, et al.: Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci. 2007; 10:870-879. (Pubitemid 47013432)
17. Li J, Daughters RS, Bullis C, et al.: The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain. 1999; 81: 25-33. (Pubitemid 29199898)
18. Berlach DM, Shir Y, Ware MA: Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med. 2006; 7: 25-29. (Pubitemid 43337701)
19. Russo EB, Mathre ML, Byrne A, et al.: Chronic cannabis use in the compassionate investigational new drug program: An examination of benefits and adverse effects of legal clinical cannabis. J Cannabis Ther. 2002; 2: 3-57. (Pubitemid 34467431)
20. Wade DT, Makela P, Robson P, et al.: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004; 10: 434-441. (Pubitemid 39117341)
21. Wade DT, Robson P, House H, et al.: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003; 17: 18-26. (Pubitemid 36230977)
22. Baker D, Pryce G, Giovannoni G, et al.: Therapeutic potential of cannabis. Lancet Neurol. 2003; 2: 291-298.
23. Wang T, Collet J, Shapiro S, et al.: Adverse effects of medical cannabinoids: A systematic review. CMAJ. 2008; 178: 1669-1678. (Pubitemid 351899653)
24. Radbruch L, Nauck F: A review of side effects and complications with cannabinoid treatment. Schmerz. 2003; 17(4): 274-279- (Pubitemid 37012319)
25. Aggarwal SK, Kyashna-Tocha M, Carter GT: Dosing medical marijuana: Rational guidelines on trial in Washington State. Med Gen Med. 2007; 9(3): 52.
26. Carter GT, Weydt P, Kyashna-Tocha M, et al.: Medical marijuana: Rational guidelines for dosing. IDrugs. 2004; 7(5): 464-470.
27. Aggarwal S, Carter GT, Steinborn J: Clearing the air: What the latest Supreme Court decision regarding medical marijuana really means. Am J Hosp Palliat Care. 2005; 22(5): 327-329. (Pubitemid 41432856)
28. Steinborn J, Chinn AK, Carter GT: The latest buzz on medicinal marijuana: A legal and medical perspective. Am J Hosp Palliat Care. 2001; 18(5):295-296.
29. Gieringer D: Medical use of cannabis: Experience in California. In Grotenhermen F, Russo E (eds.): Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Binghamton, NY: Haworth Press, 2001: 153-170.
30. Sylvestre DL, Clements BJ, Malibub Y: Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur J Gastroenterol Hepatol. 2006, 18: 1057-1063.
31. O'Connell TJ, Bou-Matar CB: Long term marijuana users seeking medical cannabis in California (2001-2007): Demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants. Harm Reduct J. 2007; 4: 16. Available at www.harmreductionjournal.com/content/4/1/16. Accessed May 10, 2009.
32. Doblin R: DEA/NIDA and the Obstruction of Privately Funded Research. Presentation at Fifth National Clinical Conference on Cannabis Therapeutics, Pacific Grove, CA, April 4-5, 2008. Available at http://sciencestage.com/v/ 10848/nida,-dea-.html. Accessed October 10, 2009.
33. Ramamurthy S, Alanmanou E, Rogers JN (eds.): Decision Making in Pain Management. Philadelphia: Mosby Elsevier, 2006: 67-75.
34. ONDCP: 2008 Marijuana Sourcebook. MARIJUANA: THE GREATEST CAUSE OF ILLEGAL DRUG ABUSE. Section: "THE 'MEDICAL MARIJUANA' ISSUE", "San Diego Marijuana Dispensaries, 2006", p. 20. Office of National Drug Control Policy Executive Office of the President. July 2008. Marijuana 08-1 [07-291. Available at www.whitehousedrugpolicy.gov/news/press08/Marijuana-2008. pdf. Accessed May 10, 2009.
35. Chapkis W, Webb RJ: Dying to Get High: Marijuana as Medicine. New York: New York University Press, 2008.
36. Reiman A: Medical cannabis patients: Patient profiles and health care utilization patterns. Complementary Health Pract Rev. 2007; 12: 31-50.
37. Corral VL: Differential effects of medical marijuana based on strain and route of administration: A three-year observational study. J Cannabis Ther. 2001; 1: 43-59.
38. Harris D, Jones RT, Shank R, et al.: Self-reported marijuana effects and characteristics of 100 San Francisco medical marijuana club members. J Addict Dis. 2000; 19: 89-103. (Pubitemid 30844246)
39. Child C, Mitchell TF, Abrams DI: Patterns of therapeutic marijuana use in two community-based cannabis buyers' cooperatives. [abstract no. 605691 Proceedings of the 12th World Conference on AIDS, Geneva, Switzerland, 1998; 12:1105. Available at http://gateway.nlm.nih.gov/MeetingAbstracts/ma:f= 102232518.html. Accessed May 10, 2009.
40. McPartland JM, Pruitt PL: Side effects of pharmaceuticals not elicited by comparable herbal medicines: The case of tetrahydrocannabinol and marijuana. Altern Ther Health Med. 1999; 5: 57-62.
41. Ben Amar M: Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol. 2006; 105: 1-25.
42. Grinspoon L, Bakalar JB: The use of cannabis as a mood stabilizer in bipolar disorder: Anecdotal evidence and the need for clinical research. J Psychoactive Drugs. 1998; 30(2): 171-177. (Pubitemid 28361019)
43. Russo EB, Burnett A, Hall B, et al.: Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005; 30(8): 1037-1043. (Pubitemid 41570039)
44. Mechoulam R, Hanus L: Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: Chemical aspects. Chem Phys Lipids. 2002; 121(1-2): 35-43.
45. Bardhi F, Sifaneck SJ, Johnson BD, et al.: Pills, thrills and bellyaches: Case studies of prescription pill use and misuse among marijuana/blunt smoking middle class young women. Contemp Drug Probl. 2007; 34(1): 53-101.
46. DEA: 2008. Available at http://justthinktwice.com/stumbleweed/rx-pot-01. htm. Accessed May 10, 2009.